Copyright
©2010 Baishideng.
World J Gastroenterol. Aug 7, 2010; 16(29): 3709-3715
Published online Aug 7, 2010. doi: 10.3748/wjg.v16.i29.3709
Published online Aug 7, 2010. doi: 10.3748/wjg.v16.i29.3709
Table 1 Patient characteristics n (%)
All patients (n = 108) | XRT (n = 33) | 5FU-RT (n = 52) | Chemo alone (n = 23) | P-value1 for XRT vs | ||
5FU-RT | Chemo alone | |||||
Age (yr) | ||||||
Median | 60 | 64 | 57 | 56 | 0.0032 | 0.032 |
Inter-quartile range | 49.5-66.0 | 57.7-68.8 | 48.0-63.7 | 49.3-65.7 | ||
Gender | ||||||
Male | 65 (60.2) | 22 (66.7) | 30 (57.7) | 13 (56.5) | 0.5 | 0.6 |
Female | 43 (39.8) | 11 (33.3) | 22 (42.3) | 10 (43.5) | ||
ECOG | ||||||
0 | 6 (5.6) | 1 (3.0) | 3 (5.8) | 2 (8.7) | 1.0 | 0.6 |
1 | 102 (94.4) | 32 (97.0) | 49 (94.2) | 21 (91.3) | ||
Helicobacter pylori status | ||||||
Yes | 36 (53.7) | 16 (66.7) | 15 (50.0) | 5 (38.5) | 0.3 | 0.2 |
No | 31 (46.3) | 8 (33.3) | 15 (50.0) | 8 (61.5) | ||
Surgical margins | ||||||
Positive | 21 (19.4) | 4 (12.1) | 14 (26.9) | 3 (13.0) | 0.2 | 1.0 |
Negative | 87 (80.6) | 29 (87.9) | 38 (73.1) | 20 (87.0) | ||
Stage | ||||||
1 or 2 | 38 (35.2) | 12 (36.4) | 14 (26.9) | 12 (52.2) | 0.5 | 0.3 |
3 or 4 | 70 (64.8) | 21 (63.6) | 38 (73.1) | 11 (47.8) | ||
Grade | ||||||
1 or 2 | 31 (28.7) | 12 (36.4) | 12 (23.1) | 7 (30.4) | 0.2 | 0.8 |
3 | 77 (71.3) | 21 (63.6) | 40 (76.9) | 16 (69.6) | ||
Albumin | ||||||
< 30 | 12 (13.3) | 4 (12.9) | 4 (10.0) | 4 (21.1) | 0.7 | 0.5 |
≥ 30 | 78 (86.7) | 27 (87.1) | 36 (90.0) | 15 (78.9) | ||
CEA | ||||||
Normal | 50 (90.9) | 17 (89.5) | 24 (92.3) | 9 (90.0) | 1.0 | 1.0 |
High | 5 (9.1) | 2 (10.5) | 2 (7.7) | 1 (10.0) | ||
Hemoglobin | ||||||
< 10 | 26 (25.7) | 8 (24.2) | 14 (29.2) | 4 (20.0) | 0.8 | 1.0 |
≥ 10 | 75 (74.3) | 25 (75.8) | 34 (70.8) | 16 (80.0) |
Table 2 Recurrence-free survival and overall survival analysis
Variable | Categories/units | n | HR (95% CI) | P-value |
Recurrence-free survival | ||||
Treatment | XRT | 108 | 1 | |
5FU-RT | 1.00 (0.508-1.959) | 1.0 | ||
Chemo only | 1.05 (0.448-2.462) | 0.9 | ||
Treatment | XRT | 108 | 1 | |
5FU-RT | 0.971 (0.477-1.966) | 0.9 | ||
Chemo only | 1.031 (0.433-2.444) | 0.9 | ||
Overall survival | ||||
Treatment | XRT | 108 | 1 | |
5FU-RT | 0.83 (0.411-1.681) | 0.6 | ||
Chemo only | 1.13 (0.474-2.677) | 0.8 | ||
Treatment | XRT | 108 | 1 | |
5FU-RT | 0.891 (0.428-1.856) | 0.8 | ||
Chemo only | 1.191 (0.494-2.882) | 0.7 |
Table 3 Recurrence-free survival and overall survival analysis
Variable | Categories/units | Chemo alone | 5FU-RT | XRT | |||
HR (95% CI) | P-value1 | HR (95% CI) | P-value1 | HR (95% CI) | P-value1 | ||
Recurrence-free survival | |||||||
ECOG | 0 | 1 | 0.9 | 1 | 1.0 | E/N = 0/1 | 0.5 |
1 | 0.92 (0.115-7.422) | 1.01 (0.238-4.326) | NE | ||||
Gender | Male | 1 | 0.9 | 1 | 0.2 | 1 | 0.5 |
Female | 0.91 (0.244-3.419) | 1.58 (0.727-3.436) | 0.65 (0.198-2.163) | ||||
Surgical margins | Positive | 1 | 0.5 | 1 | < 0.001 | 1 | 0.03 |
Negative | 0.51 (0.059-4.351) | 0.16 (0.070-0.384) | 0.27 (0.081-0.918) | ||||
Stage | 1 or 2 | 1 | 0.1 | 1 | 0.2 | 1 | 0.06 |
3 or 4 | 2.92 (0.724-11.773) | 1.86 (0.749-4.633) | 3.87 (0.853-17.586) | ||||
Grade of tumor | 1, 2 | 1 | 0.3 | 1 | 0.09 | 1 | 0.3 |
3 | 2.17 (0.444-10.636) | 2.44 (0.836-7.099) | 1.94 (0.515-7.288) | ||||
Overall survival | |||||||
ECOG | 0 | 1 | 0.8 | 1 | 0.9 | E/N = 0/1 | 0.4 |
1 | 0.78 (0.096-6.366) | 0.95 (0.220-4.069) | NE | ||||
Gender | Male | 1 | 1.0 | 1 | 0.2 | 8/22 | 0.7 |
Female | 1.02 (0.253-4.148) | 1.63 (0.740-3.598) | 0.78 (0.234-2.597) | ||||
Surgical margins | Positive | 1 | 0.004 | 1 | < 0.001 | 4/4 | 0.02 |
Negative | 0.10 (0.013-0.700) | 0.26 (0.113-0.603) | 0.25 (0.071-0.901) | ||||
Stage | 1 or 2 | 1 | 0.2 | 1 | 0.1 | 2/12 | 0.06 |
3 or 4 | 2.59 (0.646-10.412) | 2.08 (0.778-5.557) | 3.80 (0.829-17.397) | ||||
Grade of tumor | 1, 2 | 1 | 0.4 | 1 | 0.06 | 3/12 | 0.4 |
3 | 2.04 (0.418-9.944) | 3.04 (0.903-10.239) | 1.83 (0.482-6.980) |
Table 4 Subgroup analysis for overall and recurrence-free survival
Subgroup | Variable | Categories/units | n | Overall survival | Recurrence-free survival | ||
HR (95% CI) | P-value | HR (95% CI) | P-value | ||||
Surgical margins = positive | Treatment | Chemo alone | 21 | 1 | 1 | ||
5FU-RT/XRT | 0.47 (0.100–2.191) | 0.3 | 1.58 (0.206-12.154) | 0.7 | |||
Stage T3/4 | Treatment | Chemo alone | 66 | 1 | 1 | ||
5FU-RT/XRT | 0.65 (0.294–1.454) | 0.3 | 0.78 (0.352-1.709) | 0.5 | |||
Node positive | Treatment | Chemo alone | 94 | 1 | 1 | ||
5FU-RT/XRT | 0.92 (0.404–2.081) | 0.8 | 1.10 (0.489-2.482) | 0.8 |
- Citation: Tham CK, Choo SP, Poon DYH, Toh HC, Ong SYK, Tan SH, Wang MLC, Foo KF. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010; 16(29): 3709-3715
- URL: https://www.wjgnet.com/1007-9327/full/v16/i29/3709.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i29.3709